3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
23
Leukemia, Lymphocytic, Chronic, B-Cell
16
Lymphoma, Mantle-Cell
14
Lymphoma, Follicular
11
Waldenstrom Macroglobulinemia
8
Lymphoma
7
Lymphoma, B-Cell, Marginal Zone
5
Lymphoma, B-Cell
5
Recurrence
4
Lymphoma, Non-Hodgkin
3
Neoplasms
1
Multiple Myeloma
1
Lymphohistiocytosis, Hemophagocytic
1
Leukemia, B-Cell
1
Leukemia
1
Intraocular Lymphoma
1
Dendritic Cell Sarcoma, Interdigitating
1
Cardiovascular Diseases
1
Interventions
Cyclophosphamide
10
fludarabine
7
Rituximab
6
Bendamustine Hydrochloride
5
venetoclax
4
obinutuzumab
4
Lenalidomide
4
ofatumumab
3
ibrutinib
3
fludarabine phosphate
3
acalabrutinib
3
Vincristine
3
Immunotherapy, Adoptive
3
pirtobrutinib
2
Bortezomib
2
Alemtuzumab
2
zanubrutinib
1
thymoglobulin
1
tenofovir alafenamide
1
ricolinostat
1
pembrolizumab
1
pegaspargase
1
nelarabine
1
idelalisib
1
blinatumomab
1
Whole-Body Irradiation
1
Prednisolone
1
Pentostatin
1
Panobinostat
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, B-Cell
×
zanubrutinib
×
Clear all
NCT04515238
2025-06-10
CLL2-BZAG
German CLL Study Group
Phase 2
Active not recruiting
42 enrolled